World-first human trial aims to treat underlying cause of type 1 diabetes

A world-first human trial of an immunotherapy drug to treat type 1 diabetes patients has begun after decades of work by an Australian scientist. The drug is designed to rebalance the body's immune response to protect insulin-producing cells in the pancreas. It's early days but if trial is a success, it could be rolled out to a wider cohort of people.